Health
Mel Gibson Drops Two Medical Bombshells on the Joe Rogan Podcast
From The Vigilant Fox
Being familiar with alternative cancer therapies, Rogan concluded Gibson was talking about antiparasitic drugs Ivermectin and Fenbendazole, which Gibson confirmed with a nod.
In the final hour of episode #2254 of The Joe Rogan Experience, actor Mel Gibson shared two shocking medical experiences that defy mainstream knowledge.
It all started the moment Anthony Fauci’s name lept out of Gibson’s mouth.
“I don’t know why Fauci’s still walking around… or at least free,” Gibson remarked before revealing that he had “road rage” after listening to RFK Jr.’s book about Anthony Fauci.
Piling on, Joe Rogan quickly dismantled any doubts about the book’s accuracy, arguing that if it were full of lies, RFK Jr. would have been sued into the ground and publicly humiliated.
“First of all, people that don’t believe it. How come RFK Jr. didn’t get sued? How come there’s no lawsuits? If there were lies, there would be lawsuits. You’d be publicly humiliated,” Rogan pointed out.
“That book is an accurate depiction of what Anthony Fauci did during the AIDS crisis, which probably was an AZT crisis. It wasn’t an AIDS crisis.”
The first bombshell dropped when Gibson shared that he “couldn’t walk for three months” after taking Fauci’s pet drug for COVID.
“[Remdesivir] kills you. I found out that afterward. And that’s why I wonder about Fauci,” Gibson said.
“Remdesivir is so lethal it got nicknamed ‘Run Death Is Near’ after it started killing thousands of COVID patients in the hospital,” Stella Paul wrote in a previous report.
“The experts claimed that remdesivir would stop COVID; instead, it stopped kidney function, then blasted the liver and other organs.”
Unfortunately, Gibson’s gardener wasn’t as fortunate. After reportedly receiving the kidney-toxic treatment, he tragically passed away.
“I knew the guy for 20 years, and we both went to the same hospital, and he died, and I didn’t,” Gibson lamented. “I think we both got remdesivir, which is not good.”
While you’re here, please take a few seconds to subscribe for more
reports like this one.
The most jaw-dropping moment happened when Gibson made a statement that could threaten the entire cancer industry.
Gibson revealed that he has three friends who had “stage four cancer,” and now “all three of them don’t have cancer right now at all.”
“And they had some serious stuff going on,” Gibson added.
Rogan asked, “What did they take?”—to which Gibson hesitantly replied, “They took what you’ve heard they’ve taken.”
Being familiar with alternative cancer therapies, Rogan concluded Gibson was talking about antiparasitic drugs Ivermectin and Fenbendazole, which Gibson confirmed with a nod.
Corroborating what Gibson reported to Rogan, cancer surgeon Dr. Kathleen Ruddy revealed to The Epoch Times last year that she has seen several late-stage cancer patients make dramatic recoveries after taking Ivermectin.
One patient had a grim future, and then something remarkable happened. This man had stage four prostate cancer and tried all the conventional protocols before doctors told him that there was nothing they could do.
Then, he started taking ivermectin…
Within six months, the metastatic lesions began to disappear, and in less than a year, “he was out dancing for four hours” three nights per week, according to Dr. Ruddy.
A similar scenario unfolded for another man named Eddie. He was also in bad shape.
Eddie was diagnosed with two unresectable esophageal tumors that surgeons wouldn’t go near. He was a smoker, couldn’t swallow, and had lost 40 pounds in a year and a half.
“Within a couple of weeks, he sounded stronger. He could swallow. He had gained six pounds. His voice was better,” reported Dr. Ruddy.
Several weeks later, Dr. Ruddy said to Eddie, “You need to get a scan.”
Guess what happened?
“We got the scan. No tumors. Gone. Gone. The problem was that he had sold his fishing boat. That was the biggest problem. He was getting better. His tumor was gone. Now he’s got to buy another fishing boat … I was like, ‘Well, now, that’s interesting.’”
Recently, anecdotal reports have also praised Fenbendazole as a potentially miraculous anti-cancer drug.
It reportedly works by destabilizing microtubules, the structures that help cancer cells divide and grow.
By disrupting this process, Fenbendazole is believed to effectively halt cancer cell division and slow or stop tumor growth.
A case series published in 2020 documented three cancer patients who experienced complete remission after taking Fenbendazole.
“FBZ (Fenbendazole) appears to be a potentially safe and effective antineoplastic agent that can be repurposed for human use in treating genitourinary malignancies.’”
 |
Adding to the growing evidence in support of Fendendazole’s use case against cancer, an Oklahoma man credited his miraculous cancer recovery to the pet med after overcoming terminal small cell lung cancer, defying a less than 1% survival rate and leaving doctors baffled.
EDMOND, Okla. — When you tell someone a medicine for dogs cured your cancer, you better be ready for some skeptics, but Joe Tippens says it saved his life, and the lives of others.
Now, even cancer researchers are open to the possibility it might be true.
“My stomach, my neck, my liver, my pancreas, my bladder, my bones — it was everywhere,” Tippens said.
Tippens said he was told to go home, call hospice and say his goodbyes two years ago.
The doctors were unanimous, he was going to die of small cell lung cancer.
“Once that kind of cancer goes that far afield, the odds of survival are less than 1 percent, and median life expectancy is three months,” Tippens said.
Tippens said he went from 220 pounds to 110.
“I was a skeleton with skin hanging off of it,” he said. “It was difficult.”
But that was January of 2017. Today, Tippens is very much alive and what he credits for his survival has doctors scratching their heads, and the rest of us raising eyebrows.
“About half the people think I’m just crazy,” he said. “And about half the people want to know more and dig deeper.”
Tippens said he received a tip from a veterinarian, of all people. And in his desperation, he turned from people medicine to dog medicine.
Specifically, something you give your dog when it has worms.
“The truth is stranger than fiction, you know?” Tippens said, laughing.
Just three months later, Tippens says, his cancer was gone.
Thanks for reading! If you enjoyed this post, please do me a quick favor and follow this page (@VigilantFox) for more reports like this one.
From the Brownstone Institute
The US Food and Drug Administration (FDA) has approved hundreds of drugs without proof that they work—and in some cases, despite evidence that they cause harm.
That’s the finding of a blistering two-year investigation by medical journalists Jeanne Lenzer and Shannon Brownlee, published by The Lever.
Reviewing more than 400 drug approvals between 2013 and 2022, the authors found the agency repeatedly ignored its own scientific standards.
One expert put it bluntly—the FDA’s threshold for evidence “can’t go any lower because it’s already in the dirt.”
A System Built on Weak Evidence
The findings were damning—73% of drugs approved by the FDA during the study period failed to meet all four basic criteria for demonstrating “substantial evidence” of effectiveness.
Those four criteria—presence of a control group, replication in two well-conducted trials, blinding of participants and investigators, and the use of clinical endpoints like symptom relief or extended survival—are supposed to be the bedrock of drug evaluation.
Yet only 28% of drugs met all four criteria—40 drugs met none.
These aren’t obscure technicalities—they are the most basic safeguards to protect patients from ineffective or dangerous treatments.
But under political and industry pressure, the FDA has increasingly abandoned them in favour of speed and so-called “regulatory flexibility.”
Since the early 1990s, the agency has relied heavily on expedited pathways that fast-track drugs to market.
In theory, this balances urgency with scientific rigour. In practice, it has flipped the process. Companies can now get drugs approved before proving that they work, with the promise of follow-up trials later.
But, as Lenzer and Brownlee revealed, “Nearly half of the required follow-up studies are never completed—and those that are often fail to show the drugs work, even while they remain on the market.”
“This represents a seismic shift in FDA regulation that has been quietly accomplished with virtually no awareness by doctors or the public,” they added.
More than half the approvals examined relied on preliminary data—not solid evidence that patients lived longer, felt better, or functioned more effectively.
And even when follow-up studies are conducted, many rely on the same flawed surrogate measures rather than hard clinical outcomes.
The result: a regulatory system where the FDA no longer acts as a gatekeeper—but as a passive observer.
Cancer Drugs: High Stakes, Low Standards
Nowhere is this failure more visible than in oncology.
Only 3 out of 123 cancer drugs approved between 2013 and 2022 met all four of the FDA’s basic scientific standards.
Most—81%—were approved based on surrogate endpoints like tumour shrinkage, without any evidence that they improved survival or quality of life.
Take Copiktra, for example—a drug approved in 2018 for blood cancers. The FDA gave it the green light based on improved “progression-free survival,” a measure of how long a tumour stays stable.
But a review of post-marketing data showed that patients taking Copiktra died 11 months earlier than those on a comparator drug.
It took six years after those studies showed the drug reduced patients’ survival for the FDA to warn the public that Copiktra should not be used as a first- or second-line treatment for certain types of leukaemia and lymphoma, citing “an increased risk of treatment-related mortality.”
Elmiron: Ineffective, Dangerous—And Still on the Market
Another striking case is Elmiron, approved in 1996 for interstitial cystitis—a painful bladder condition.
The FDA authorized it based on “close to zero data,” on the condition that the company conduct a follow-up study to determine whether it actually worked.
That study wasn’t completed for 18 years—and when it was, it showed Elmiron was no better than placebo.
In the meantime, hundreds of patients suffered vision loss or blindness. Others were hospitalized with colitis. Some died.
Yet Elmiron is still on the market today. Doctors continue to prescribe it.
“Hundreds of thousands of patients have been exposed to the drug, and the American Urological Association lists it as the only FDA-approved medication for interstitial cystitis,” Lenzer and Brownlee reported.
“Dangling Approvals” and Regulatory Paralysis
The FDA even has a term—”dangling approvals”—for drugs that remain on the market despite failed or missing follow-up trials.
One notorious case is Avastin, approved in 2008 for metastatic breast cancer.
It was fast-tracked, again, based on ‘progression-free survival.’ But after five clinical trials showed no improvement in overall survival—and raised serious safety concerns—the FDA moved to revoke its approval for metastatic breast cancer.
The backlash was intense.
Drug companies and patient advocacy groups launched a campaign to keep Avastin on the market. FDA staff received violent threats. Police were posted outside the agency’s building.
The fallout was so severe that for more than two decades afterwards, the FDA did not initiate another involuntary drug withdrawal in the face of industry opposition.
Billions Wasted, Thousands Harmed
Between 2018 and 2021, US taxpayers—through Medicare and Medicaid—paid $18 billion for drugs approved under the condition that follow-up studies would be conducted. Many never were.
The cost in lives is even higher.
A 2015 study found that 86% of cancer drugs approved between 2008 and 2012 based on surrogate outcomes showed no evidence that they helped patients live longer.
An estimated 128,000 Americans die each year from the effects of properly prescribed medications—excluding opioid overdoses. That’s more than all deaths from illegal drugs combined.
A 2024 analysis by Danish physician Peter Gøtzsche found that adverse effects from prescription medicines now rank among the top three causes of death globally.
Doctors Misled by the Drug Labels
Despite the scale of the problem, most patients—and most doctors—have no idea.
A 2016 survey published in JAMA asked practising physicians a simple question—what does FDA approval actually mean?
Only 6% got it right.
The rest assumed that it meant the drug had shown clear, clinically meaningful benefits—such as helping patients live longer or feel better—and that the data was statistically sound.
But the FDA requires none of that.
Drugs can be approved based on a single small study, a surrogate endpoint, or marginal statistical findings. Labels are often based on limited data, yet many doctors take them at face value.
Harvard researcher Aaron Kesselheim, who led the survey, said the results were “disappointing, but not entirely surprising,” noting that few doctors are taught about how the FDA’s regulatory process actually works.
Instead, physicians often rely on labels, marketing, or assumptions—believing that if the FDA has authorized a drug, it must be both safe and effective.
But as The Lever investigation shows, that is not a safe assumption.
And without that knowledge, even well-meaning physicians may prescribe drugs that do little good—and cause real harm.
Who Is the FDA Working for?
In interviews with more than 100 experts, patients, and former regulators, Lenzer and Brownlee found widespread concern that the FDA has lost its way.
Many pointed to the agency’s dependence on industry money. A BMJ investigation in 2022 found that user fees now fund two-thirds of the FDA’s drug review budget—raising serious questions about independence.
Yale physician and regulatory expert Reshma Ramachandran said the system is in urgent need of reform.
“We need an agency that’s independent from the industry it regulates and that uses high-quality science to assess the safety and efficacy of new drugs,” she told The Lever. “Without that, we might as well go back to the days of snake oil and patent medicines.”
For now, patients remain unwitting participants in a vast, unspoken experiment—taking drugs that may never have been properly tested, trusting a regulator that too often fails to protect them.
And as Lenzer and Brownlee conclude, that trust is increasingly misplaced.
- Investigative report by Jeanne Lenzer and Shannon Brownlee at The Lever [link]
- Searchable public drug approval database [link]
- See my talk: Failure of Drug Regulation: Declining standards and institutional corruption
Republished from the author’s Substack
Author
The Red Deer Regional Health Foundation is thrilled to announce the winners of this year’s Red Deer Hospital Lottery prizes – including the Dream Home, a $100,000.00 cash prize, and Mega Bucks 50.
James Smith of Spruce View has won the $100,000.00 cash prize.
Montey Brehaut of Red Deer has won the Mega Bucks 50 jackpot, taking home $301,702.50.
The grand prize Sorento Custom Homes Dream Home, including furnishings by Urban Barn and worth $1,074,472 – has been awarded to Oscar Gunnlaugson of Sylvan Lake.
The winner announcements took place at noon on June 26 , 2025 – and was streamed live on Facebook from Red Deer Regional Hospital Center.
“We’re excited to celebrate this year’s winners and deeply grateful to everyone who supported the lottery,” said Manon Therriault, CEO of the Red Deer Regional Health Foundation. “Funds raised will directly enhance patient care at Red Deer Regional Hospital Centre.”
This year’s lottery proceeds will fund essential new and replacement equipment, ensuring Red Deer Regional Hospital Center can continue to serve the 500,000 people who rely on it. While plans for the hospital expansion move forward, healthcare doesn’t wait. Patients in our community need access
to life-saving technology today, and supporting Red Deer Hospital Lottery has made that possible.
A full list of winners, including electronics prize recipients, will be posted on July 2 at reddeerhospitallottery.ca.
Winners will also receive instructions on how to claim their prizes by mail.
The keys to the Dream Home will be presented at a special ceremony this summer.
The Quiet Invasion: How Transnational Crime and Chinese State Actors Infiltrated Vancouver and Eroded Canada’s Sovereignty
Boxing authority says allegedly male competitor should return Olympic medal won against women
Canada’s euthanasia regime is not health care, but a death machine for the unwanted
Alberta’s government is investing $5 million to help launch the world’s first direct air capture centre at Innisfail
-
Automotive1 day agoPower Struggle: Electric vehicles and reality
-
Alberta5 hours agoAlberta Independence Seekers Take First Step: Citizen Initiative Application Approved, Notice of Initiative Petition Issued
-
Automotive1 day agoElectric vehicle sales are falling hard in BC, and it is time to recognize reality.
-
Business1 day agoTrump on Canada tariff deadline: ‘We can do whatever we want’
-
Business7 hours agoCanada Caves: Carney ditches digital services tax after criticism from Trump
-
Brownstone Institute2 days ago
FDA Exposed: Hundreds of Drugs Approved without Proof They Work
-
Crime7 hours agoSuspected ambush leaves two firefighters dead in Idaho
-
Energy1 day agoChina undermining American energy independence, report says